Efficacy of azithromycin in the treatment of cutaneous leishmaniasis
| Autor: | Fabiano Geraldo Pimenta Junior, Mario León Silva-Vergara, Laércio Costa, Luiz Eduardo Ramirez Giraldo, Edvá Vieira de Paula, Alejandro J. Krolewiecki, Ademir Rocha, Jaime Costa Silva, Aluízio Prata |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2003 |
| Předmět: |
Microbiology (medical)
Adult Male medicine.medical_specialty lcsh:Arctic medicine. Tropical medicine Adolescent lcsh:RC955-962 Leishmaniasis Cutaneous Physical examination Pilot Projects Azithromycin Treatment failure Drug Administration Schedule Leishmania braziliensis Leishmania Viannia brasiliensis chemistry.chemical_compound Cutaneous leishmaniasis Internal medicine Biopsy medicine Animals Humans Child Aged Azitromicina medicine.diagnostic_test biology business.industry Middle Aged medicine.disease biology.organism_classification Leishmaniose cutânea Surgery Anti-Bacterial Agents Pentavalent antimonial Infectious Diseases Disease evolution Treatment Outcome chemistry Child Preschool Parasitology Female business medicine.drug Follow-Up Studies |
| Zdroj: | Revista da Sociedade Brasileira de Medicina Tropical, Vol 36, Iss 1, Pp 65-69 (2003) Revista da Sociedade Brasileira de Medicina Tropical v.36 n.1 2003 Revista da Sociedade Brasileira de Medicina Tropical Sociedade Brasileira de Medicina Tropical (SBMT) instacron:SBMT Revista da Sociedade Brasileira de Medicina Tropical, Volume: 36, Issue: 1, Pages: 65-69, Published: JAN 2003 |
| ISSN: | 1678-9849 0037-8682 |
| Popis: | The present open pilot study was conducted to assess the efficacy of azithromycin for the treatment of patients with cutaneous leishmaniasis in Araçuaí and Varzelândia, MG. Twenty-four patients with less of six months of disease evolution were treated after clinical examination, Montenegro test and a biopsy. The treatment schemes consisted of oral doses of 500 mg per day for 3, 5 and 10 days and of 1000 mg for two days. A clinical control was performed monthly and treatment cycles were repeated when necessary until full reepithelialization of the lesions. On the occasion of the final evaluation, 20 patients had completed the study and 17 of them (85%) were cured. The time to obtain a cure was 60 days ifor 6 (30%) patients, 90 days for 7 (35%), and 120 for 4 (20%). The three patients with treatment failure received a pentavalent antimonial for 20 days. No adverse reactions to the medication were observed and a 14 month follow-up did not show recurrence in any patient. These results suggest that azithromycin can be a good therapeutic option for the treatment of cutaneous leishmaniasis caused by Leishmania Viannia brasiliensis. O presente estudo piloto aberto avaliou a eficácia da Azitromicina em pacientes com leishmaniose cutânea, em Araçuaí e Varzelândia, MG. Foram tratados 24 pacientes após exame clínico, teste de Montenegro, e biópsia, e que tivessem menos de seis meses de evolução da doença. Os esquemas de tratamento empregaram doses, pela via oral, de 500 mg por dia durante 3,5 e 10 dias e de 1000 mg durante dois dias. Mensalmente foi realizado controle clínico e quando necessário, repetidos ciclos do medicamento, até reepitelização completa das lesões. Na avaliação final 20 pacientes terminaram o estudo, dos quais 17 (85%) foram curados. O tempo de cura foi de 60 dias em 6 (30%) pacientes, de 90 dias em 7 (35%) e de 120 dias em 4 (20%). Os três pacientes que tiveram falha terapêutica receberam antimonial pentavalente durante 20 dias. Não foram observadas reações adversas ao medicamento e o seguimento até 14 meses pós-tratamento não mostrou recidiva em nenhum dos pacientes. Estes resultados sugerem que a Azitromicina pode ser uma boa opção terapêutica para o tratamento de leishmaniose cutânea causada por Leishmania Viannia brasiliensis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|